Health Union Recognized Among Fastest-Growing Companies by Financial Times

Health Union made the list with a 247.2% annual growth rate in revenue between 2017 and 2020 and a 51.4% compound annual growth rate.

Survey: Focal Seizures Lead to Complex Epilepsy Treatment Journey

Respondents with focal seizures were more likely than those who aren’t to currently be using prescription medications and various alternative therapies.

Survey: Treatment Plan Discussions Differ from Adherence Challenges

With the highest percentage, 27% of respondents said they viewed cost as a challenge to staying on their medication as prescribed or instructed.

Health Union Ranks No. 449 in 2021 Deloitte Technology Fast 500

Health Union ranked No. 449 on Deloitte’s 2021 Technology Fast 500™, continuing to experience exponential growth since the company started in 2010.

Quality of Life Impact Research Presented at Three Fall Conferences

The findings focus on the patient-reported impact of cystic fibrosis, hidradenitis suppurativa and spondyloarthritis on various quality of life factors.

10th Annual WEGO Health Awards Winners Announced

WEGO Health announces its 2021 class of WEGO Health Awards honorees, including winners in 16 patient leader categories and six industry categories.

New Data at DPE 2021: Social Health Has Reinvented the Patient Journey

95% of survey respondents use online social resources for health reasons; 3/4 use these resources at critical inflection points in their patient journey

Survey: People with Chronic Dry Eye Experience Various Misconceptions

Nearly half of Chronic Dry Eye In America 2021 survey respondents said that others don’t understand what they’re going through with chronic dry eye.

Health Union Announces 4th Consecutive Inc. 5000 Win

Health Union ranks in the top 40% of companies on the 2021 Inc. 5000 list and in the top 20% among companies headquartered in the city of Philadelphia.

Advanced Ovarian Cancer: Condition Control, But Screening Frustration

There is not currently a specific, effective screening test for early detection of ovarian cancer, a point 82% of respondents expressed frustration about.